The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

FARGO, N.D. (Valley News Live) - Changes are coming to the way schizophrenia is treated. The US Food and Drug Administration ...

Scientists have developed a new brain-mapping tool called START, which combines transcriptomics and viral tracing to map the ...

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Recent research is painting a clearer picture of the link between the use of clozapine for schizophrenia and respiratory ...

Bristol-Myers Squibb Company (BMY) shares rose 1.6% after the FDA approved its new drug for schizophrenia. Shares of Cassava Sciences (SAVA) plunged 10.6% after the company reached a $40 million ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.The ...

The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

The US Food and Drug Administration (FDA) has approved xanomeline and trospium chloride capsules (Cobenfy) for the treatment of schizophrenia in adults. The drug is the first antipsychotic treatment ...